Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Hans H Adomat"'
Autor:
Ingrid Elisia, Hisae Nakamura, Vivian Lam, Elyse Hofs, Rachel Cederberg, Jessica Cait, Michael R Hughes, Leora Lee, William Jia, Hans H Adomat, Emma S Guns, Kelly M McNagny, Ismael Samudio, Gerald Krystal
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0152538 (2016)
Dimethyl sulfoxide (DMSO) is currently used as an alternative treatment for various inflammatory conditions as well as for cancer. Despite its widespread use, there is a paucity of data regarding its safety and efficacy as well as its mechanism of ac
Externí odkaz:
https://doaj.org/article/91c73280fe8c430c8a2ae7863e8eae20
Autor:
Syed Imran Ali Shah, Hannah C. P. Wilson, Paul D. Abel, Richard J. Wassersug, Vít Třebický, Jitka Třebická Fialová, Caroline Allen, Hans H. Adomat, Robert H. Bell, Emma S. Tomlinson Guns, S. Craig Roberts
Publikováno v:
Journal of Men's Health, Vol 17, Iss 3, Pp 69-76 (2021)
Background and objective: Luteinizing hormone-releasing hormone agonists (LHRHa) suppress gonadal hormone production and are commonly used to treat prostate cancer (PC) in men and conditions ranging from uterine fibroids to estrogen-sensitive cancers
Externí odkaz:
https://doaj.org/article/98d3502b0b924755995720504d5d9087
Autor:
Christopher P. Evans, Allen C. Gao, Martin E. Gleave, Emma S. Tomlinson Guns, Hans H. Adomat, Chengfei Liu, Joy C. Yang, Vito Cucchiara
Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. Degarelix (Firmagon), a gonadotropin-releasing hormone (GnRH) receptor antagonist differs from luteinizing hormone-releasing hormone (LHRH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::341fa5d7c1bd08e07b1e186e57d38e03
https://doi.org/10.1158/1535-7163.c.6537793.v1
https://doi.org/10.1158/1535-7163.c.6537793.v1
Autor:
Christopher P. Evans, Allen C. Gao, Martin E. Gleave, Emma S. Tomlinson Guns, Hans H. Adomat, Chengfei Liu, Joy C. Yang, Vito Cucchiara
Suppl. Figure1. Western blots of AR-FL and AR-V7 of A. CWR22Rv1 B. VCaP cells treated with leuprolide or degarelix. Suppl. Figure 2. Western blots of AR-V7 in representative tumor lysates from control, castration, leuprolide and degarelix groups.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4221fc6421e5d15b69df3dd5f0060bd4
https://doi.org/10.1158/1535-7163.22504603.v1
https://doi.org/10.1158/1535-7163.22504603.v1
Autor:
Michael E. Cox, Kishor M. Wasan, Colm Morrissey, Peter S. Nelson, Collin C. Collins, Shancheng Ren, Yen-Yi Lin, Emma S. Tomlinson Guns, Hans H. Adomat, Gang Wang, Fatemeh Derakhshan, Ankur Midha, Jake W. Noble, Jacob A. Gordon
Aberrant cholesterol metabolism is increasingly appreciated to be essential for prostate cancer initiation and progression. Transcript expression of the high-density lipoprotein-cholesterol receptor scavenger receptor B1 (SR-B1) is elevated in primar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971b2fbddc65e3ca834ce740246a0d31
https://doi.org/10.1158/0008-5472.c.6510765
https://doi.org/10.1158/0008-5472.c.6510765
Autor:
Michael E. Cox, Kishor M. Wasan, Colm Morrissey, Peter S. Nelson, Collin C. Collins, Shancheng Ren, Yen-Yi Lin, Emma S. Tomlinson Guns, Hans H. Adomat, Gang Wang, Fatemeh Derakhshan, Ankur Midha, Jake W. Noble, Jacob A. Gordon
Supplementary information describing methods for cell culture, HDL assay,qPCR and western blotting analysis, steroid analysis and BLT-1 pharmacokinetic analysis. Supplemental statistical analysis of IHC samples and results of in vivo profiling of BLT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45cde30f0b2f0cdd0f33e5962962bd6b
https://doi.org/10.1158/0008-5472.22420821
https://doi.org/10.1158/0008-5472.22420821
Autor:
Colleen C. Nelson, Michael Pollak, Martin E. Gleave, Adrian Herington, Vanessa Thompson, Hans H. Adomat, Jennifer A. Locke, Stephen C. Hendy, Jennifer H. Gunter, Amy A. Lubik
Androgen-dependent pathways regulate maintenance and growth of normal and malignant prostate tissues. Androgen deprivation therapy (ADT) exploits this dependence and is used to treat metastatic prostate cancer; however, regression initially seen with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f5c23d406e7feb5287189c2179a9167
https://doi.org/10.1158/0008-5472.c.6503180.v1
https://doi.org/10.1158/0008-5472.c.6503180.v1
Autor:
Colleen C. Nelson, Michael Pollak, Martin E. Gleave, Adrian Herington, Vanessa Thompson, Hans H. Adomat, Jennifer A. Locke, Stephen C. Hendy, Jennifer H. Gunter, Amy A. Lubik
PDF file - 228K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bf8153c9124bb40f43f8a1ff251732
https://doi.org/10.1158/0008-5472.22391180.v1
https://doi.org/10.1158/0008-5472.22391180.v1
Autor:
Amy A, Lubik, Mannan, Nouri, Sarah, Truong, Mazyar, Ghaffari, Hans H, Adomat, Eva, Corey, Michael E, Cox, Na, Li, Emma S, Guns, Parvin, Yenki, Steven, Pham, Ralph, Buttyan
Publikováno v:
International journal of cancer. 140(2)
Despite the substantial benefit of androgen deprivation therapy (ADT) for metastatic prostate cancer, patients often progress to castration-resistant disease (CRPC) that is more difficult to treat. CRPC is associated with renewed androgen receptor ac
Autor:
Mary Rose, Pambid, Rachel, Berns, Hans H, Adomat, Kaiji, Hu, Joanna, Triscott, Norbert, Maurer, Natalia, Zisman, Vijay, Ramaswamy, Cynthia E, Hawkins, Michael D, Taylor, Christopher, Dunham, Emma, Guns, Sandra E, Dunn
Publikováno v:
Pediatric bloodcancer. 61(1)
Molecular subtyping has allowed for the beginning of personalized treatment in children suffering from medulloblastoma (MB). However, resistance inevitably emerges against these therapies, particularly in the Sonic Hedgehog (SHH) subtype. We found th